The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Idefirix® becomes the first and only product recommended by SMC for the desensitization of highly sensitized patients waiting for a kidney transplant1 · SMC considers Idefirix® to be a clinically effective and cost-effective treatment within current clinical practice 1 · This is an important milestone for highly sensitized Scottish patients awaiting a kidney transplant, as NHS Scotland funding for Idefirix® will now be made available to hospitals in Scotland · The SMC decision follows the recent positive NICE recommendation for Idefirix® in England, Wales and Northern Ireland,2